Related Experiment Video
Updated: Jan 31, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Development of next-generation peptide vaccination therapy
Abstract:
Identification of tumor-associated antigens (TAAs) recognized by T cells has enabled clinical peptide vaccination trials targeting TAAs to be performed for patients with carcinoma or sarcoma. Although peptide vaccination could elicit specific immunological responses, clinical objective responses were not frequently observed, especially in end-stage patients with large tumor burdens who were receiving high-dose chemotherapy. The key points for developing effective peptide vaccination therapy are (i) targeting cancer stem-like cell antigens that are expressed in cancer cells but not in normal cells and regulating tumorigenesis and (ii) manip- ulating memory T stem cells that have the capacity of long-living and resistance to chemo- therapeutic drugs. The combination of a peptide vaccination and immune checkpoint inhibi- tors might also be attractive.
Insights
Effective cancer peptide vaccination requires targeting cancer stem-like cell antigens and manipulating memory T stem cells. Combining peptide vaccines with immune checkpoint inhibitors may improve outcomes for cancer patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- T cell-identified tumor-associated antigens (TAAs) have led to peptide vaccination trials for carcinoma and sarcoma.
- Current peptide vaccination strategies show limited clinical responses, particularly in advanced cancer patients undergoing chemotherapy.
Purpose of the Study:
- To identify key strategies for developing more effective peptide vaccination therapies.
- To explore novel targets and approaches for enhancing anti-cancer immunity.
Main Methods:
- Review and analysis of existing peptide vaccination strategies and clinical trial outcomes.
- Identification of critical factors for successful T cell-mediated cancer therapy.
Main Results:
- Effective peptide vaccination necessitates targeting cancer stem-like cell antigens.
- Manipulating long-living, chemotherapy-resistant memory T stem cells is crucial.
- Combination therapy with immune checkpoint inhibitors shows potential.
Conclusions:
- Future peptide vaccination therapies should focus on cancer stem-like cell antigens and memory T stem cell manipulation.
- Combining peptide vaccination with immune checkpoint inhibitors may enhance clinical efficacy in cancer treatment.
Related Concept Videos
Vaccinations
Peptide Bonds
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Gene Therapy
Group Therapy
Sustainable Development

